REPAGLINIDE UNITED STATES PHARMACOPEIA

Code: 1600813-200MG D2-231

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseas...


read more

Your Price
€400.52 EACH
€492.64 inc. VAT
REQUEST

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Biochem/physiol Actions

Repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. It represents a new class of insulin secretagogues, structurally unrelated to sulphonylureas, which were developed for the treatment of type 2 diabetes.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

USP issued SDS can be found here.

Sales restrictions may apply.

application(s)pharmaceutical (small molecule)
formatneat
Gene Informationhuman ... ABCC8(6833), KCNJ11(3767)
gradepharmaceutical primary standard
InChI keyFAEKWTJYAYMJKF-QHCPKHFHSA-N
InChI1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
manufacturer/tradenameUSP
SMILES stringCCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(O)=O
Cas Number135062-02-1
This product has met the following criteria: